Information Provided By: 
Fly News Breaks for September 28, 2015
EPZM
Sep 28, 2015 | 07:04 EDT
After new data on Epizymne's solid tumor treatment tazemetostat,was presented, RBC Capital thinks the data is significantly positive. The firm says that, "the Phase I results clearly demonstrate clinical activity for tazemetostat in a heavily pre-treated patient population with poor prognosis." It keeps an Outperform rating on the shares.
News For EPZM From the Last 2 Days
There are no results for your query EPZM
